A Multicenter Trial Defining a Serum Protein Signature Associated with Pancreatic Ductal Adenocarcinoma

Table 3

Consensus signatures of antibodies based on the highest combined score from 10 backward elimination iterations. Shown within brackets is the individual antibody clone suffix (for markers targeted by multiple antibody clones).

PDAC versus NPC	Score	PDAC versus OPD	Score
IL-11 (2)	291.4	MAPK1 (3)	276.5
IL-6 (7)	288.1	C5 (2)	273
Cystatin C (1)	286.9	TNFRSF3 (1)	265.5
C1 inh. (3)	279.2	TNFRSF3 (2)	260.9
Angiomotin (1)	276	UCHL5	259.6
IL-13 (2)	272.9	IL-4 (3)	258.7
IL-13 (3)	270.7	Factor B (3)	258
CD40 (1)	270.6	Apo-A4 (3)	257.5
HADH2 (3)	270.4	KSYK-1	255.2
HADH2 (4)	269.7	Sox11A	253.1
C1 inh. (4)	269.4	CD40L	252.2
C1 inh. (2)	269.2	Apo-A1 (1)	251.4
LDL (2)	268.1	CIMS (13)	250.1
GAK (3)	268	BTK (2)	246.1
C3 (1)	266.1	GM-CSF (5)	245
CIMS (5)	264.3	TGF-β1 (2)	239.5
C1q	261.1	PTP-1B (2)	237.2
CD40 (4)	259.6	MCP-1 (7)	235.1
IL-8 (2)	259.4	UPF3B (1)	232.5
C5 (2)	258.5	C1 inh. (4)	228.3
ATP-5B (3)	257.1	Sialyl Lewis x	227.6
Factor B (4)	256.2	IL-3 (1)	225.8
CIMS (10)	253.6	IL-9 (2)	224.2
TNF-α (3)	253.5	HADH2 (2)	222.7
Eotaxin (3)	248.4	IL-4 (4)	222.4